Blepharitis Market Research Report - Forecast to 2027

Blepharitis Market Research Report: Type (Anterior Blepharitis, Posterior Blepharitis, Mixed Blepharitis) Treatment (Eye Cleansers, Antibiotic Therapy) Diagnosis (Physical Examination) End User (Hospitals, Specialty Centers) – Global forecast till 2027

ID: MRFR/Pharma/4311-HCR | | Region: Global | 100 pages

Market Scenario


Blepharitis is an ophthalmologic disorder which causes inflammation of the eyelids that leads to eye irritation. It is a common eye disorder that is caused by either bacteria or a skin condition like dandruff from the scalp or overproduction of oil from the glands of the eyelids.


The global blepharitis market is majorly driven by rising prevalence of ophthalmological disorders, such as dry eye, uveitis among others. Additionally, factors such as government initiatives, rising demand for advanced treatment, increasing awareness among mass regarding eye care, and growing market players offering newer products for the treatment of blepharitis are likely to drive the market. Similarly, the involvement of leading players in new product development and upgrading their existing products to boost their product portfolio is boosting the growth of global blepharitis market.


For instance, WHO estimated that over 285 million people were visually impaired in 2014 and approximately 24.4 million Americans aged 40 had a cataract. Similarly, according to reports published by the United Kingdom Statistics Authority, in 2015, around 15,900 people were registered as visually impaired. This rising prevalence of ophthalmological disorders is likely to enhance the growth of global blepharitis market.


Global Blepharitis Market is expected to grow at a CAGR of 6.5% during the forecast period.


 Blepharitis Market Figure: Global Blepharitis Market, by Region, 2016 (%)


Source: World Health Organization, Centers for Disease Control and Prevention, expert interview, annual report, white paper, company presentation, market research future analysis


 Intended Audience



  • Pharmaceutical Manufacturers and Suppliers

  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors


Research Methodology:


 Bronchitis Methodology


Source: World Health Organization, Centers for Disease Control and Prevention, Expert Interview, Annual Report, White Paper, Company Presentation, and Market Research Future Analysis


Segments  


The global blepharitis market is segmented on the basis of type, treatment, diagnosis, and end user.


 On the basis of type, the market is segmented into anterior blepharitis, posterior blepharitis, and mixed blepharitis.


On the basis of treatment, the market is segmented into eye cleansers, artificial tears, and antibiotic therapy. Antibiotic therapy segment is further sub-segmented into topical antibiotic therapy and oral antibiotic therapy.


 On the basis of diagnosis, the market is segmented into the physical examination, comprehensive eye examination, and others.


On the basis of the end user, the market is segmented into specialty centers, hospitals, and others.


Regional Analysis


North America Blepharitis market is a growing market. On a regional basis, the Americas region is segmented into North America and South America. North America is segmented into the U.S. and Canada. Increasing incidence of eye disorders, along with rising awareness among population regarding eye care is likely to drive the market. Additionally, growing healthcare expenditure and rising involvement of leading players in new product development and rising government support is likely to enhance the growth of blepharitis market in North America. For instance, according to the Centers for Medicare & Medicaid Services, in 2015, the U.S. healthcare spending increased by 5.8% reaching USD 3.2 trillion.


Europe is the second largest market and holds a healthy share in the global blepharitis market. The European market is expected to grow at a healthy CAGR during the forecast period owing to the large pool of market players offering innovative products and rising skilled medical professionals along with growing demand for better and advanced healthcare infrastructure. For instance, according to the Organization for Economic Co-operation and Development (OECD), the healthcare expenditure in Germany was EUR 321 billion in 2014.This growing healthcare expenditure is driving the blepharitis market in Europe.


Asia Pacific is expected to be the fastest growing market. Increasing population eventually leading to rising patient population, rising prevalence of eye disorders are the major driver for the market growth. China is the fastest growing region owing to an increasingly older population. Rising awareness about the health and growing demand for healthcare facilities in emerging economies drive the market in this region. Rising healthcare expenditure and rise in awareness among the masses is driving the growth of blepharitis market in the Asia Pacific region.


The Middle East & Africa is expected to show the least growth in the market due to some major factors such as lack of awareness and limited treatment facilities. In the Middle East, United Arab Emirates is the largest market share owing to the development of healthcare industry and rising demand for advanced specialty centers.


Key Players       


Some of the key players in the Blepharitis market are InSite Vision Incorporated, NovaBay Pharmaceuticals, Inc., Scope Ophthalmics Ltd, Thea Pharmaceuticals Limited, Perrigo Laboratories, Merck & Co., Galderma S.A., and Novartis AG.



Frequently Asked Questions (FAQ) :


Blepharitis is an ophthalmological disorder which causes inflammation of the eyelids, leading to irritation of the eye.

Blepharitis Market is expected to exhibit a strong 6.5% CAGR over the forecast period till 2027.

Increasing awareness about eye diseases is the major driver for the Blepharitis Market.

Americas hold a dominant 45% share in the global Blepharitis Market.

Leading players in the Blepharitis include InSite Vision Inc., NovaBay, and Scope Ophthalmics, among others.

Table of Content

1. Report Prologue

2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

6. Global Blepharitis Market, by Type

6.1 Introduction

6.2 Anterior Blepharitis

6.2.1 Market Estimates & Forecast, 2020–2027

6.3 Posterior Blepharitis

6.3.1 Market Estimates & Forecast, 2020–2027

6.4 Mixed Blepharitis

6.4.1 Market Estimates & Forecast, 2020–2027

7. Global Blepharitis Market, by Diagnosis

7.1 Introduction

7.2 Physical Examination

7.2.1 Market Estimates & Forecast, 2020–2027

7.3 Comprehensive Eye Examination

7.3.1 Market Estimates & Forecast, 2020–2027

7.4 Others

7.4.1 Market Estimates & Forecast, 2020–2027

8. Global Blepharitis Market, by Treatment

8.1 Introduction

8.2 Eye Cleansers

8.2.4 Market Estimates & Forecast, 2020–2027

8.3 Artificial Tears

8.3.1.1 Market Estimates & Forecast, 2020–2027

8.4 Antibiotic Therapy

8.4.1 Topical Antibiotic Therapy

8.4.2 Oral Antibiotic Therapy

8.4.3 Market Estimates & Forecast, 2020–2027

9. Global Blepharitis Market, by End-User

9.1 Introduction

9.2 Hospitals

9.2.1 Market Estimates & Forecast, 2020–2027

9.3 Specialty Centers

9.3.1 Market Estimates & Forecast, 2020–2027

9.4 Others

9.4.1 Market Estimates & Forecast, 2020–2027

10 Global Blepharitis Market, by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 U.S.

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 U.K.

10.3.1.4 Italy

10.3.1.5 Spain

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest of the Middle East & Africa

11 Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

12 Company Profiles

12.1 Scope Ophthalmics Ltd

12.1.1 Company Overview

12.1.2 Product Overview

12.1.3 Financials

12.1.4 SWOT Analysis

12.2 NovaBay Pharmaceuticals, Inc.

12.2.1 Company Overview

12.2.2 Product Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Thea Pharmaceuticals Limited

12.3.1 Company Overview

12.3.2 Product Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Perrigo Laboratories

12.4.1 Company Overview

12.4.2 Product/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 Merck & Co.

12.5.1 Company Overview

12.5.2 Product Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.6 Galderma S.A.

12.6.1 Company Overview

12.6.2 Product Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.7 Novartis AG

12.7.1 Overview

12.7.2 Product Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Others

13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of Pharmaceutical Industry

14 Appendix

LIST OF TABLES

Table 1 Blepharitis Industry Synopsis, 2020–2027

Table 2 Global Blepharitis Market Estimates and Forecast, 2020–2027, (USD Million)

Table 3 Global Blepharitis Market, by Region, 2020–2027, (USD Million)

Table 5 Global Blepharitis Market, by Treatment, 2020–2027, (USD Million)

Table 6 Global Blepharitis Market, by Diagnosis, 2020–2027, (USD Million)

Table 7 Global Blepharitis Market, by End-User, 2020–2027, (USD Million)

Table 8 North America Blepharitis Market, by Treatment, 2020–2027, (USD Million)

Table 9 North America Blepharitis Market, by Diagnosis, 2020–2027, (USD Million)

Table 10 North America Blepharitis Market, by End-User, 2020–2027, (USD Million)

Table 11 US Blepharitis Market, by Treatment, 2020–2027, (USD Million)

Table 12 US Blepharitis Market, by Diagnosis, 2020–2027, (USD Million)

Table 13 US Blepharitis Market, by End-User, 2020–2027, (USD Million)

Table 14 Canada Blepharitis Market, by Treatment, 2020–2027, (USD Million)

Table 15 Canada Blepharitis Market, by Diagnosis, 2020–2027, (USD Million)

Table 16 Canada Blepharitis Market, by End-User, 2020–2027, (USD Million)

Table 17 South America Blepharitis Market, by Treatment, 2020–2027, (USD Million)

Table 18 South America Blepharitis Market, by Diagnosis, 2020–2027, (USD Million)

Table 19 South America Blepharitis Market, by End-User, 2020–2027, (USD Million)

Table 20 Europe Blepharitis Market, by Treatment, 2020–2027, (USD Million)

Table 21 Europe Blepharitis Market, by Diagnosis, 2020–2027, (USD Million)

Table 22 Europe Blepharitis Market, by End-User, 2020–2027, (USD Million)

Table 23 Western Europe Blepharitis Market, by Treatment, 2020–2027, (USD Million)

Table 24 Western Europe Blepharitis Market, by diagnosis, 2020–2027, (USD Million)

Table 25 Western Europe Blepharitis Market, by End-User, 2020–2027, (USD Million)

Table 26 Eastern Europe Blepharitis Market, by Treatment, 2020–2027, (USD Million)

Table 27 Eastern Europe Blepharitis Market, by diagnosis, 2020–2027, (USD Million)

Table 28 Eastern Europe Blepharitis Market, by End-User, 2020–2027, (USD Million)

Table 29 Asia Pacific Blepharitis Market, by Treatment, 2020–2027, (USD Million)

Table 30 Asia Pacific Blepharitis Market, by diagnosis, 2020–2027, (USD Million)

Table 31 Asia Pacific Blepharitis Market, by End-User, 2020–2027, (USD Million)

Table 32 Middle East & Africa Blepharitis Market, by Treatment, 2020–2027, (USD Million)

Table 33 Middle East & Africa Blepharitis Market, by diagnoses, 2020–2027, (USD Million)

Table 34 Middle East & Africa Blepharitis Market, by End-User, 2020–2027, (USD Million)


LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Blepharitis Market

Figure 3 Segmentation Market Dynamics for Blepharitis Market

Figure 4 Global Blepharitis Market Share, by Treatment 2020

Figure 5 Global Blepharitis Market Share, by Diagnosis 2020

Figure 6 Global Blepharitis Market Share, by End-User, 2020

Figure 7 Global Blepharitis Market Share, by Region, 2020

Figure 8 North America Blepharitis Market Share, by Country, 2020

Figure 9 Europe Blepharitis Market Share, by Country, 2020

Figure 10 Asia Pacific Blepharitis Market Share, by Country, 2020

Figure 11 Middle East & Africa Blepharitis Market Share, by Country, 2020

Figure 12 Global Blepharitis Market: Company Share Analysis, 2020 (%)

Figure 13 NovaBay Pharmaceuticals, Inc: Key Financials

Figure 14 NovaBay Pharmaceuticals, Inc: Segmental Revenue

Figure 16 NovaBay Pharmaceuticals, Inc: Geographical Revenue

Figure 17 Scope Ophthalmics Ltd.: Key Financials

Figure 18 Scope Ophthalmics Ltd.: Segmental Revenue

Figure 19 Scope Ophthalmics Ltd.: Geographical Revenue

Figure 20 Thea Pharmaceuticals Limited: Key Financials

Figure 21 Thea Pharmaceuticals Limited: Segmental Revenue

Figure 22 Thea Pharmaceuticals Limited: Geographical Revenue

Figure 23 Novartis AG: Key Financials

Figure 24 Novartis AG: Segmental Revenue

Figure 25 Novartis AG: Geographical Revenue

Figure 26 Perrigo Laboratories: Key Financials

Figure 27 Perrigo Laboratories: Segmental Revenue

Figure 28 Perrigo Laboratories. Geographical Revenue

Figure 29 Ardelyx, Inc.: Key Financials

Figure 30 Ardelyx, Inc.: Segmental Revenue

Figure 31 Ardelyx, Inc.: Geographical Revenue

Figure 32 Novartis AG. Key Financials

Figure 33 Novartis AG. Segmental Revenue

Figure 34 Novartis AG. Geographical Revenue